Fixed Phage News

Fixed Phage secures further £1.5m investment to scale programmes in Animal, Veterinary and Human Health

DATE: 14th December 2022

Glasgow-based Biotechnology business, Fixed Phage, secures £1.5m follow-on investment to further scale development and commercialisation of bacteriophage technology in the fight against antimicrobial resistance.

The latest funding round has seen current investors, including Scottish Enterprise and London Scottish Investment Partners join a follow-on round to support the commercialisation of key programmes, which include the development and commercialisation of phage-based solutions in Animal & Veterinary health, as well as planning and development for Human health applications.

David Browning, CEO of Fixed Phage said:

The follow-on investment demonstrates how the company has continued to develop well-validated programmes leveraging robust phage technology, particularly in Animal & Veterinary health, with ambitious plans toward key programmes in human health. Underpinned by strong investor support to translate the technology to address antimicrobial resistance, the Company is well-positioned to develop, commercialise, and apply phage-based solutions to the market. 

Kerry Sharp, Director of Entrepreneurship and Investment at Scottish Enterprise, said:

We’ve supported Fixed Phage with both investment and grant support since its start-up stage, so it’s great to see the company continue its growth trajectory with this latest investment. It is a highly innovative company with strong growth prospects, as well as the ability to provide solutions to some of the world’s most pressing animal and human health concerns. 

About Fixed Phage:

Fixed Phage is a biotechnology company developing and commercialising unique, proprietary, anti-infective technologies based on bacteriophage immobilisation and stabilisation. It is developing a well-proven and comprehensively patented surface modification technology, that irreversibly attaches and stabilises bacteriophages on a wide range of carrier materials, thereby creating biologically active interventions.

Bacteriophages are natural antibiotics that can target and kill problem bacteria while leaving the beneficial bacteria intact. They are biodegradable and made from renewable materials.

Fixed Phage’s technology can be applied across several industries including Aquaculture, Animal and Human Health & Wellbeing.

About Scottish Enterprise: 

Scottish Enterprise (SE) is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. It supports businesses to innovate and scale to transform the Scottish economy by focusing on new market opportunities through targeted investment, innovation, and internationalisation. You can also follow them on Twitter and LinkedIn.

For more information get in touch with us.

Related Articles